Cancer Care Program 2008

Annual Oncology Report

Includes data collected through 2007

University of Michigan Health System

THOMSON REUTERS TOP HOSPITALS NATIONAL 2007

Allegiance HEALTH

205 N. East Avenue • Jackson, MI 49201 • (517) 780-7280

Compiled, December 2008

chairman's report

Report Focus: **Cancer Care Excellence Close to Home**

John Axelson, MD
Hematology & Oncology Associates
Allegiance Health Cancer Committee Chairman
2003 - 2007

I am pleased to introduce the seventh issue of the Allegiance Health Oncology Annual Report for calendar year 2007. The five most prevalent cancer diagnoses within Allegiance Health in 2007 were lung, breast, prostate, bladder and colon. The focus of this year's report is prostate cancer, the fourth most commonly detected malignancy at Allegiance Health.

I would like to extend my gratitude and a special thank you to my colleagues on the Cancer Committee at Allegiance Health for their commitment, dedication, and on-going investment to our cancer program and community. 2007 was an exciting year for the cancer program with many accomplishments.

- **January 2007** - Intensity Modulated Radiation Therapy (IMRT) technology became operational, providing Radiation Oncologists advanced delivery technology for better dose distribution to the tumor and sparing to surrounding normal tissue.
- **March 2007** - The oncology program underwent a rigorous audit by the American College of Surgeon division of Commission on Cancer (CoC). Our program was awarded a three-year certification with accommodations. Nationally, only 25 percent of cancer programs are CoC certified and we are proud to be recognized as one.
- **March 2007** - A large-bore CT Simulator was installed in Radiation Oncology to assist physicians with advanced treatment planning and positioning of patients. Thank you Allegiance Auxiliary members of the and Jackson community for your continued support at our annual "Pink Ball".
- **March 2007** - The latest evolution in robotic surgery–the da Vinci® Surgical System–was acquired, enabling surgeons to operate with unmatched precision and controls. Patients now have the most effective, least invasive surgical treatment available for prostate cancer.
- **The Ray H. Clark Cancer Research Program** - Clinical trial enrollment for cancer cases increased from four to six percent. Increased enrollment is directly related to our collaboration with the NCI clinical trial programs that participates in the Michigan Cancer Research Consortium Community Clinical Oncology Program (MCRC-CCOP). We are one of 50 participating research programs. Our involvement provides the Jackson community with over 100 cooperative groups Phase II and III trials for both cancer prevention and treatment. For more information on MCRC-COOP trials available for each primary site, please visit **www.mcrconline.org**.

Similarly, in 2008, we look forward to further improvements such as a prostate brachytherapy program, digital mammography, and an on-site nurse navigator for our patients. I hope you will take a moment to read through the following pages to learn more about the cancer care program at Allegiance Health.

Our Cancer Registry Data Base, operational since 2001, collects data on over 4,800 cancer patients who have received care in our community. We now have five years of survival data on breast cancer as a result of this comprehensive database.

cancer screening guidelines

Taking Action **Against Cancer**

Cancer Screening Guidelines

(Source: American Cancer Society, 2006)

Breast Cancer

- Annual mammograms starting at age 40 (earlier for high risk women)
- Clinical breast exam every three years for women in their 20s and 30s, and every year for women 40 and older
- Report any breast changes promptly
- Breast self-exam for women starting in their 20s

Cervical Cancer

- Screening should begin approximately three years after a women begins having vaginal intercourse, but no later than 21 years of age.
- Annual screening with regular Pap tests or every two years using liquid-based tests
- At or after age 30, women who have had three normal test results in a row may get screened every 2-3 years absent of any high-risk factors.
- Women 70 and older who have had three or more consecutive Pap tests in the last ten years may choose to stop cervical cancer screening.
- Screening after a total hysterectomy (with removal of the cervix) is not necessary unless the surgery was done as a treatment for cervical cancer.

Colorectal Cancer

Men and women age 50 and over:

- A fecal occult blood test (FOBT) every year
- A flexible sigmoidoscopy (FSIG) every five years
- A double-contrast barium enema every five years
- A colonoscopy every ten years

Prostate Cancer

Men age 50 and over:

- Annual prostate-specific antigen (PSA) test and the digital rectal examination (DRE)
- Men at high risk (African-American men and men with a strong family history of one or more first-degree relatives diagnosed with prostate cancer at an early age) should begin testing at age 45.
- Information should be provided about what is known and uncertain about the benefits and limitations of early detection and treatment of prostate CA for informed decision making.

cancer registry overview

During 2007, a total of 820 new cancer cases were diagnosed as part of Allegiance Health's Cancer Care Program. Of those cases, 755 were analytic cases, meaning the patients received all or part of their first course of treatment through Allegiance providers. Another 65 cases were non-analytic cases, meaning patients received their initial treatment elsewhere and were referred to Allegiance providers for subsequent treatment.

Allegiance Health 2007 Primary Site Table

PRIMARY SITE	TOTAL	PERC	SEX		CLASS OF CASE		ALIVE	EXP	AJCC STAGE FOR ANALYITCAL CASES							Benign Brain & CNS
			M	F	Analy	Non-Analy			0	1	2	3	4	Unstageable	N/A	
BREAST	**139**	**17**	**1**	**138**	**127**	**12**	**128**	**11**	**19**	**53**	**28**	**19**	**8**	**0**	**0**	**0**
BRONCHUS AND LUNG	**136**	**16.6**	**72**	**64**	**132**	**4**	**69**	**67**	**0**	**19**	**9**	**33**	**66**	**4**	**1**	**0**
PROSTATE GLAND	**130**	**15.9**	**130**	**0**	**117**	**13**	**122**	**8**	**0**	**0**	**110**	**4**	**3**	**0**	**0**	**0**
BLADDER	**55**	**6.7**	**45**	**10**	**50**	**5**	**47**	**8**	**24**	**10**	**7**	**2**	**7**	**0**	**0**	**0**
COLON	**46**	**5.6**	**22**	**24**	**46**	**0**	**40**	**6**	**1**	**6**	**12**	**15**	**12**	**0**	**0**	**0**
KIDNEY	32	3.9	15	17	30	2	28	4	0	20	3	1	5	0	1	0
HEMATOPOIETIC/RETICULOEN	31	3.8	16	15	21	10	21	10	0	0	0	0	1	0	20	0
STOMACH	24	2.9	18	6	24	0	15	9	0	5	0	3	8	4	4	0
LYMPH NODES	21	2.6	12	9	18	3	19	2	0	1	6	7	4	0	0	0
BRAIN	19	2.3	15	4	16	3	15	4	0	0	0	0	0	0	16	1
LARYNX	17	2.1	15	2	16	1	14	3	1	5	2	3	5	0	0	0
CORPUS UTERI	17	2.1	0	17	16	1	14	3	0	10	3	0	2	1	0	0
THYROID GLAND	17	2.1	5	12	17	0	17	0	0	9	2	4	2	0	0	0
UNKNOWN PRIMARY SITE	15	1.8	4	11	13	2	3	12	0	0	0	0	0	0	13	0
PANCREAS	12	1.5	7	5	10	2	4	8	0	1	1	1	6	1	0	0
SKIN	9	1.1	5	4	8	1	7	2	1	4	0	1	2	0	0	0
TESTIS	9	1.1	9	0	9	0	8	1	0	6	0	2	1	0	0	0
ESOPHAGUS	7	0.9	6	1	7	0	5	2	0	1	3	0	3	0	0	0
RECTOSIGMOID JCT	7	0.9	2	5	6	1	5	2	1	1	0	1	2	1	0	0
RECTUM	7	0.9	6	1	6	1	5	2	0	0	3	1	2	0	0	0
CONN, SUBQ AND OTH SOFT	7	0.9	5	2	7	0	7	0	0	1	0	2	0	4	0	0
CERVIX UTERI	7	0.9	0	7	7	0	6	1	6	0	0	1	0	0	0	0
LIVER-INTRAHEP BILE DCTS	6	0.7	5	1	6	0	4	2	0	0	0	2	4	0	0	0
OVARY	5	0.6	0	5	3	2	3	2	0	1	1	0	1	0	0	0
BASE OF TONGUE	4	0.5	2	2	4	0	3	1	0	1	0	2	1	0	0	0
VULVA	4	0.5	0	4	3	1	3	1	2	0	0	0	0	1	0	0
TONSIL	3	0.4	3	0	3	0	3	0	0	0	0	2	1	0	0	0
OTHER ILL-DEFINED SITES	3	0.4	3	0	2	1	2	1	0	0	0	0	0	0	2	0
LIP	2	0.2	2	0	2	0	1	1	0	2	0	0	0	0	0	0
FLOOR OF MOUTH	2	0.2	0	2	2	0	2	0	0	0	0	0	2	0	0	0
PAROTID GLAND	2	0.2	2	0	2	0	1	1	0	0	1	0	1	0	0	0
NASOPHARYNX	2	0.2	1	1	2	0	2	0	0	0	1	0	1	0	0	0
SMALL INTESTINE	2	0.2	1	1	2	0	1	1	0	0	0	0	0	0	2	0
OTH & UNSPEC PTS OF BILI	2	0.2	2	0	2	0	0	2	0	0	2	0	0	0	0	0
RETROPERITONEUM AND PERI	2	0.2	1	1	2	0	2	0	0	1	0	0	1	0	0	0
PENIS	2	0.2	2	0	2	0	2	0	0	1	1	0	0	0	0	0
OTHER URINARY ORGS	2	0.2	2	0	2	0	1	1	0	0	1	0	0	1	0	0
OTH PARTS OF MOUTH	1	0.1	1	0	1	0	0	1	0	0	0	1	0	0	0	0
OROPHARYNX	1	0.1	1	0	1	0	1	0	0	0	0	1	0	0	0	0
PYRIFORM SINUS	1	0.1	1	0	1	0	1	0	0	0	0	1	0	0	0	0
HYPOPHARYNX	1	0.1	0	1	1	0	1	0	0	0	0	1	0	0	0	0
ANUS AND ANAL CANAL	1	0.1	0	1	1	0	1	0	1	0	0	0	0	0	0	0
ACCESSORY SINUSES	1	0.1	0	1	1	0	1	0	0	0	0	1	0	0	0	0
HEART, MEDIASTINUM	1	0.1	0	1	1	0	1	0	0	0	0	0	1	0	0	0
BONES, JNTS, ART CART	1	0.1	0	1	1	0	0	1	0	0	0	0	1	0	0	0
OTH FEMALE GENITAL ORGS	1	0.1	0	1	1	0	1	0	0	0	0	0	0	0	1	0
OTHER MALE GENITAL ORGS	1	0.1	1	0	1	0	1	0	0	0	0	0	0	0	1	0
URETER	1	0.1	1	0	1	0	1	0	0	0	1	0	0	0	0	0
EYE AND ADNEXA	1	0.1	0	1	1	0	1	0	0	0	0	0	0	0	1	0
MENINGES	1	0.1	0	1	1	0	0	1	0	0	0	0	0	0	0	1
TOTAL	**820**	**100**	**441**	**379**	**755**	**65**	**639**	**181**	**56**	**158**	**197**	**111**	**153**	**17**	**62**	**2**

prostate cancer

2007 Registry Data Prostate Cancer Statistics

The Cancer Registry for the Cancer Care Program of Allegiance Health is a data-collection system used to manage and analyze case data to provide a clear reading of the types and numbers of cases that occur in the Allegiance Health service area. Data on new cancer cases each year is tracked and recorded according to malignancy. The data collected includes patient demographics, information concerning the tumor location, size, type and treatment. Patient identity is excluded from the database to protect patient confidentiality.









cancer committee

The Cancer Care Program at Allegiance Health is led by an effective group of oncologists and other cancer specialists who direct the quality standards of the program, including continuing staff education and accreditation requirements. In addition to sharing expertise on cancer treatments and initiatives, these dedicated professionals work tirelessly to incorporate new technology into treatment planning and meet every patient need.

The committee is comprised of:

Physician Members 2007

John Axelson MD, Hematology & Oncology, Cancer Committee Chairman

Richard V. A. Dieterele, MD, Director, Pathology

Michael Sheth, MD, Pain Management

Amy Schultz, MD, Community Health & Prevention, Community Outreach Coordinator

Julie Soriano, MD, Radiation Oncologist, Cancer Liaison Physician

Anil Tibrewal MD, General Surgeon

David Williamson, MD, Radiology

Additional Members 2007

Deborah Dusseau, BS, RT, Manager, Radiation Oncology & Cancer Registry

Susan Caines, BSN, MBA Quality Management

Jill Drewno, RN, OP IV Services

Joan Ezinga, RN, Women's Health Center

Mary Floros, CTR, RHIT, Cancer Registrar

Nyoshini Govender, RBScPT, Manager, Outreach Services

Terrance Keys, Executive Director, Neuromusculo Skeletal Services, Imaging Services/Radiation Oncology,

Robin Kirkpatrick, Director, Marketing

Lil McGaffigan, BSN, RN Case Management

Laurie Collier, RN, Clinical Trial Coordinator

Rachel Wheeler, RN, Nurse Manager, Medical Oncology Unit

cancer research

Hematology and Oncology Associates, along with Allegiance Health, jointly operate the Ray H. Clark Cancer Research Program and maintain an affiliation with the University of Michigan Cancer Care Network. This relationship allows our patients direct access to clinical trial protocols (cancer research) available through the National Cancer Institute.

In 2007, 6% of analytical patients enrolled in clinical trials.

Supporting Programs and Services

Case Management

Cancer Conference

Center for Pain Management

Allegiance Health Hospice Home

Home Care Services

Hospice of Jackson

Imaging Services

Inpatient Hospice Care

Inpatient Oncology

Outpatient Chemotherapy

Outpatient IV Services

Pastoral Care

Pharmacy

Radiation Oncology

Registered Dietitians

Rehabilitation Services

Local Support Groups

Living Stronger Together (chronic illnesses)

RENEW (breast/gynecological cancer)

Man to Man (prostate cancer)

important phone numbers

Medical Oncologists

Hematology and Oncology Associates . . . 789-7122
Central Clinic, P.C. 787-8371

Radiation Oncologists

Paul Tejada Center for
Radiation Oncology 780-7299

Access Center
(24-hours crisis counseling line) 789-5971
Case Management Department 788-4950
Center for Pain Management 788-4841
Allegiance Health Home Care 841-6984
Allegiance Health Hospice 841-6983
Allegiance Health Hospice Home 817-7600
Ray H. Clark Cancer Research Program 841-1413
Support Group Information 780-7299

Outpatient IV Services 788-4922
Pastoral Care 788-4889
Patient Representative 788-4740
Pharmacy 788-4817
Registered Dietitians 787-3806
Rehabilitation Services
Inpatient 788-4704
Outpatient 788-4856
Lymphedema Clinic 780-7252

online resources

National Comprehensive Cancer Network
www.nccn.com

American Cancer Society
www.cancer.org

National Cancer Institute **1-800-4CANCER**
www.cancer.gov

Center for Disease Control
www.cdc.gov/cancer/screenforlife

Allegiance Health
www.AllegianceHealth.org

Michigan Cancer Research Consortium
www.mcrconline.org

To determine Medicare coverage
1-800-MEDICARE

People Living with Cancer
www.plwc.org

American College of Surgeons
www.facs.org

allegiance health location map